[1]李玉龙,宗 伟,常素娥,等.微小RNA-195通过靶向BIRC5调控肝癌Hep3B细胞凋亡实验研究[J].陕西医学杂志,2022,51(3):270-273,279.[doi:DOI:10.3969/j.issn.1000-7377.2022.03.002]
　LI Yulong,ZONG Wei,CHANG Su'e,et al.Experimental study of miRNA-195 regulating apoptosis of hepatoma Hep3B cells by targeting BIRC5[J].,2022,51(3):270-273,279.[doi:DOI:10.3969/j.issn.1000-7377.2022.03.002]
点击复制

微小RNA-195通过靶向BIRC5调控肝癌Hep3B细胞凋亡实验研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
51
期数:
2022年3期
页码:
270-273,279
栏目:
基础研究
出版日期:
2022-03-05

文章信息/Info

Title:
Experimental study of miRNA-195 regulating apoptosis of hepatoma Hep3B cells by targeting BIRC5
作者:
李玉龙1; 宗 伟1; 常素娥2; 陈思攀3
(1.陕西省人民医院消化内科,陕西 西安 710068; 2.西安交通大学第二附属医院骨科,陕西 西安 710004; 3.陕西省人民医院介入放射科,陕西 西安 710068)
Author(s):
LI Yulong; ZONG Wei; CHANG Su'e; CHEN Sipan
(Department of Gastroenterology,Shaanxi Provincial People's Hospital,Xi'an 710068,China)
关键词:
肝癌;  微小RNA-195;  靶基因;  细胞增殖;  细胞凋亡;  BIRC5
Keywords:
Liver cancer;  miR-195;  Target gene;  Cell proliferation;  Cell apoptosis;  BIRC5
分类号:
R 735.7
DOI:
DOI:10.3969/j.issn.1000-7377.2022.03.002
文献标志码:
A
摘要:
目的:探讨微小RNA-195(miR-195)对肝癌Hep3B细胞凋亡的影响,并探索其下游靶基因。方法:采用MTT实验、流式细胞仪检测miR-195对肝癌Hep3B细胞增殖及凋亡的影响。构建双荧光素酶报告基因质粒,采用双荧光素酶报告基因实验验证靶标分子。采用RNA干扰技术检测沉默BIRC5对肝癌Hep3B细胞增殖及凋亡的影响。结果:与miR-ctrl组相比,miR-195过表达可抑制肝癌Hep3B细胞增殖,促进其凋亡。双荧光素酶报告基因实验表明,miR-195可靶向作用BIRC5,沉默BIRC5可抑制肝癌Hep3B细胞增殖,促进其凋亡。结论:miR-195可通过靶向调控BIRC5抑制肝癌Hep3B细胞增殖,促进其凋亡。BIRC5可能是肝癌靶向治疗的重要靶标。
Abstract:
Objective:To investigate the effect of microRNA-195(miR-195)on apoptosis of hepatoma Hep3B cells and explore its downstream target genes.Methods:MTT assay and flow cytometry were used to detect the effect of miR-195 on the proliferation and apoptosis of hepatoma Hep3B cells.Dual luciferase reporter gene vector was constructed,and double fluorescent reporter gene experiment was used to verify the targeting relationship between them.The effects of silencing BIRC5 on proliferation and apoptosis of hepatoma Hep3B cells were detected by RNA interference.Results:Compared with miR-ctrl group,miR-195 overexpression could inhibit the proliferation and promote the apoptosis of hepatoma Hep3B cells.Double fluorescent reporter gene experiment showed that miR-195 could target BIRC5,and silencing BIRC5 could inhibit the proliferation and promote apoptosis of hepatoma Hep3B cells.Conclusion:MiR-195 can inhibit the proliferation and promote the apoptosis of hepatoma Hep3B cells by targeting BIRC5.BIRC5 may be an important target for targeted therapy of liver cancer.

参考文献/References:

[1] Cronin KA,Lake AJ,Scott S,et al.Annual report to the nation on the status of cancer,part Ⅰ:National cancer statistics[J].Cancer,2018,124(13):2785-2800.
[2] 司海龙,马仰仰,马一鸣,等.培元抗癌汤联合替加氟对小鼠H22肝癌细胞生长的抑制作用[J].陕西中医,2021,42(9):1155-1158.
[3] Wong CM,Wong CC,Lee JM,et al.Sequential alterations of microRNA expression in hepatocellular carcinoma development and venous metastasis[J].Hepatology,2012,55(5):1453-1461.
[4] Chen F,Li XF,Fu DS,et al.Clinical potential of miRNA-221 as a novel prognostic biomarker for hepatocellular carcinoma[J].Cancer Biomark,2017,18(2):209-214.
[5] Chen L,Chu F,Cao Y,et al.Serum miR-182 and miR-331-3p as diagnostic and prognostic markers in patients with hepatocellular carcinoma[J].Tumour Biol,2015,36(10):7439-7447.
[6] Yin J,Hou P,Wu Z,et al.Circulating miR-375 and miR-199a-3p as potential biomarkers for the diagnosis of hepatocellular carcinoma[J].Tumour Biol,2015,36(6):4501-4507.
[7] Chen X,Wang A.Clinical significance of miR-195 in hepatocellular carcinoma and its biological function in tumor progression[J].Onco Targets Ther,2019,12:527-534.
[8] Yu S,Jing L,Yin XR,et al.MiR-195 suppresses the metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by inhibiting YAP[J].Oncotarget,2017,8(59):99757-99771.
[9] Yan JJ,Chang Y,Zhang YN,et al.MiR-195 inhibits cell proliferation via targeting AEG-1 in hepatocellular carcinoma[J].Oncol Lett,2017,13(5):3118-3126.
[10] Yang X,Yu J,Yin J,et al.MiR-195 regulates cell apoptosis of human hepatocellular carcinoma cells by targeting LATS2[J].Pharmazie,2012,67(7):645-651.
[11] Vasaikar SV,Straub P,Wang J,et al.Linkedomics:Analyzing multi-omics data within and across 32 cancer types[J].Nucleic Acids Res,2018,46(1):956-963.
[12] 廖 琦.晚期肝癌患者疼痛及生存质量调查研究[J].陕西医学杂志,2016,45(7):925-927.
[13] 曹绍华,王庆庆,张金冉.索拉非尼联合卡培他滨治疗肝细胞肝癌疗效及对患者血清miR-212和miR-132水平的影响[J].陕西医学杂志,2020,49(5):615-618.
[14] Altieri DC,Marchisio PC.Survivin apoptosis:An interloper between cell death and cell proliferation in cancer[J].Lab Invest,1999,79(11):1327-1333.
[15] 王秀文,符立梧.凋亡抑制蛋白(IAP):抗癌新靶点[J].中国药理学通报,2004,20(2):129-133.
[16] Li F,Altieri DC.Transcriptional analysis of human survivin gene expression[J].Biochem J,1999,344(2):305-311.
[17] Dai JB,Zhu B,Lin WJ,et al.Identification of prognostic significance of BIRC5 in breast cancer using integrative bioinformatics analysis[J].Bioscience Reports,2020,40(2):3678.
[18] Monzó M,Rosell R,Felip E,et al.A novel anti-apoptosis gene:Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers[J].J Clin Oncol,1999,17(7):2100-2104.
[19] 王 梅,王 冰,王晓丽,等.凋亡相关基因survivin在子宫颈癌组织中的表达及其与bcl-2、p53基因表达相关性的初步研究[J].中华妇产科杂志,2001,36(9):546-548.
[20] Conway EM,Pollefeyt S,Cornelissen J,et al.Three differentially expressed survivin cDNA variants encode proteins with distinct antiapoptotic functions[J].Blood,2000,95(4):1435-1442.
[21] Kelly RJ,Lopez-Chavez A,Citrin D,et al.Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin[J].Mol Cancer,2011,10:35.
[22] Xu R,Lin L,Zhang B,et al.Identification of prognostic markers for hepatocellular carcinoma based on the epithelial-mesenchymal transition-related gene BIRC5[J].BMC Cancer,2021,21(1):687.

相似文献/References:

[1]张慧贤,马向明,付庆江,等.肝细胞癌患者血清IL-17细胞因子水平检测的临床意义[J].陕西医学杂志,2016,(10):1394.
[2]苏艳丽,冯 军.血栓弹力图和常规凝血四项检测在评估肝癌患者围术期凝血功能中的应用研究*[J].陕西医学杂志,2019,(7):846.
　SU Yanli,FENG Jun..Application of thromboelastography and conventional coagulation in evaluating perioperative coagulation function in patients with liver cancer[J].,2019,(3):846.
[3]吴许军,李文阳,张甲戌.靶向肝癌抗肿瘤疫苗临床研究进展[J].陕西医学杂志,2022,51(12):1611.[doi:DOI:10.3969/j.issn.1000-7377.2022.12.034]
　WU Xujun,LI Wenyang,ZHANG Jiaxu.Clinical research progress of targeted anti-tumor vaccines for hepatocellular carcinoma[J].,2022,51(3):1611.[doi:DOI:10.3969/j.issn.1000-7377.2022.12.034]
[4]曹振振,韩会会,杨文义.肝癌患者血清成纤维细胞生长因子21和富亮氨酸α2糖蛋白1表达情况及临床意义[J].陕西医学杂志,2023,52(3):305.[doi:DOI:10.3969/j.issn.1000-7377.2023.03.013]
　CAO Zhenzhen,HAN Huihui,YANG Wenyi.Expression of FGF21 and LRG1 in serum of patients with hepatocellular carcinoma and its clinical diagnostic value[J].,2023,52(3):305.[doi:DOI:10.3969/j.issn.1000-7377.2023.03.013]
[5]董 勇,程 序,梁 晗,等.肝癌组织角蛋白23表达与患者临床病理特征及预后关系研究[J].陕西医学杂志,2023,52(6):756.[doi:DOI:10.3969/j.issn.1000-7377.2023.06.026]
　DONG Yong,CHENG Xu,LIANG Han,et al.Relationship between keratin 23 expression and clinicopathological features and prognosis of patients with hepatocellular carcinoma[J].,2023,52(3):756.[doi:DOI:10.3969/j.issn.1000-7377.2023.06.026]
[6]惠玉洁,朱林凤,李卫民,等.宫颈癌患者血清微小RNA-195、双皮质素样激酶1、鳞状细胞癌抗原表达水平与临床病理特征及预后相关性研究[J].陕西医学杂志,2024,(5):696.[doi:DOI:10.3969/j.issn.1000-7377.2024.05.027]
　HUI Yujie,ZHU Linfeng,LI Weimin,et al.Relationship between serum microRNA-195,doublecortin-like kinase 1,squamous cell carcinoma antigen levels and clinicopathological featuresand prognosis in patients with cervical cancer[J].,2024,(3):696.[doi:DOI:10.3969/j.issn.1000-7377.2024.05.027]
[7]濮忠建,杨 军,杨 帆,等.基于长链非编码RNA HOX转录反义RNA探讨次乌头原碱对人肝癌SK-Hep-1细胞自噬的影响实验研究[J].陕西医学杂志,2024,(6):754.[doi:DOI:10.3969/j.issn.1000-7377.2024.06.007]
　PU Zhongjian,YANG Jun,YANG Fan,et al.Effect of protopine on autophagy in human liver cancer SK-Hep-1 cells based on lncRNA HOTAIR[J].,2024,(3):754.[doi:DOI:10.3969/j.issn.1000-7377.2024.06.007]
[8]吴 洁,田鑫越,秦耐宇,等.艾司氯胺酮对肝癌细胞恶性生物学行为的影响及作用机制实验研究[J].陕西医学杂志,2024,(8):1041.[doi:DOI:10.3969/j.issn.1000-7377.2024.08.007]
　WU Jie,TIAN Xinyue,QIN Naiyu,et al.Effect of esketamine on malignant biological behavior of hepatocellular carcinoma cells and its mechanism[J].,2024,(3):1041.[doi:DOI:10.3969/j.issn.1000-7377.2024.08.007]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金资助项目(81601081); 陕西省自然科学基础研究计划项目(2020JM-654)
更新日期/Last Update: 2022-03-04